A Phase 4 interventional study of Aspirin in Pregnancy Induced Hypertension (PIH), sponsored by Dr. Sunita Pun. Not yet recruiting. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-28.
Sponsored by Dr. Sunita Pun · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 52 studies testing aspirin in Pre-Eclampsia — 18 open to participants now, 22 under way, 5 of them phase 3. Aspirin · Pre-Eclampsia.
Among the 52 studies testing aspirin in Pre-Eclampsia, this one is the 39th largest by planned enrollment, is one of 4 that started in 2026, is one of 16 in phase 4, reaches primary completion later than 9 of the 21 other live ones, and was the 49th registered.
918 studies on the registry are indexed under Pre-Eclampsia; 243 are open to participants now.
Browse Pre-Eclampsia studies →18 of the 52 studies testing aspirin in Pre-Eclampsia are open now, in 11 countries. Recruiting first, the newest first:
University of Calgary · Sites in Belgium, Canada, Denmark and 4 more countries
Ages 18+ · Women only
Medicare Hospital (Pvt) Limited · Sites in Pakistan
Ages 18–45 · Women only
NYU Langone Health · Sites in United States
Ages 18–50 · Women only
Thomas Jefferson University · Sites in United States
Ages 16–55 · Women only
Ohio State University · Sites in United States
Ages 14–35 · Women only
By country, each count listing its studies:
Aspirin: first FDA approval 1950 (PERCODAN), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 160 Pre-Eclampsia studies recruiting now, 79 (49%) set no upper age limit and 80 (50%) stop at 75 or younger; 18 take children under 18; 59 take healthy volunteers.
This study: 18 Years and older · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
52 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 9 · Phase 3 13 · Phase 4 16
First in 2001; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 86 is below the median of 110 across 482 interventional studies indexed under Pre-Eclampsia.
Median enrollment 235 across the 52 interventional studies. Of the 19 that completed or were terminated, 5 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 52 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Dr. Sunita Pun as lead sponsor.
Dr. Sunita Pun has 1 study filed under Pre-Eclampsia — fewer than ten, so there is no comparison to draw.
6 of the studies testing aspirin in Pre-Eclampsia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05924971MemorialCare Health SystemAspirin for Postpartum Patients With Preeclampsia | 2026-12 |
| NCT04479072University of ChicagoAspirin and Preeclampsia | 2026-12-01 |
| NCT07373756Dr. Sunita PunRandomized Controlled Study to Compare Efficacy of Aspirin 75mg and 150mg In the Prevention of Preeclampsia In High Risk Pregnant Women | 2026-12-31 |
| NCT06281665Malamo CountourisTreatment With Aspirin After Preeclampsia: TAP Trial | 2027-01-01 |
| NCT07041385Shalamar HospitalComparing the Efficacy of 75mg Versus 150mg Aspirin for the Prevention of Preeclampsia in High-Risk Pregnant Women | 2027-06-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 52 studies testing aspirin in Pre-Eclampsia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Preeclampsia in pregnancy is a dreaded complication which has both fetal and maternal adverse outcomes. Studies and WHO have advocated that this complication can be prevented by Aspirin. However which dose is more effective in preventing preeclampsia, whether 75mg or 150mg, will be known from this study.
Preeclampsia is a leading cause of maternal and perinatal morbidity and mortality worldwide, particularly in low- and middle-income countries. It is a multisystem disorder of pregnancy characterized by new-onset hypertension after 20 weeks of gestation, often accompanied by proteinuria or evidence of end-organ dysfunction. The pathophysiology of preeclampsia involves abnormal placentation, endothelial dysfunction, increased platelet activation, and an imbalance between vasoconstrictive and vasodilatory prostaglandins.
Low-dose Aspirin (acetylsalicylic acid) has been shown to reduce the risk of preeclampsia through irreversible inhibition of cyclooxygenase-1 (COX-1), resulting in reduced thromboxane A2 production, decreased platelet aggregation, and improved uteroplacental perfusion. International guidelines recommend prophylactic low-dose Aspirin for pregnant women at high risk of preeclampsia; however, there is ongoing debate regarding the optimal dose. Both 75 mg and 150 mg doses are currently used in clinical practice, but comparative evidence in South Asian populations, including Nepal, remains limited.
This investigator-initiated, non-commercial randomized controlled trial is designed to compare the effectiveness and safety of Aspirin 75 mg versus Aspirin 150 mg once daily for the prevention of preeclampsia in pregnant women identified as high risk based on a high gestosis score. The study is conducted at a tertiary-level teaching hospital in Kathmandu, Nepal.
Participants will be enrolled during early pregnancy and randomized in a 1:1 allocation ratio to receive either Aspirin 75 mg or Aspirin 150 mg orally once daily. Randomization will be generated using a computer-based random sequence with block randomization to ensure balance between treatment groups. Allocation concealment will be achieved using sequentially numbered, opaque, sealed envelopes prepared by an independent individual not involved in participant recruitment or outcome assessment.
Due to the difference in tablet strength, the trial is open-label. To minimize bias, all participants will receive identical standard antenatal care according to institutional and national guidelines, and outcome assessment will follow predefined diagnostic criteria. Data analysis will be conducted by investigators blinded to treatment allocation.
The investigational product will be administered from enrollment until 36 weeks of gestation or delivery, whichever occurs earlier. Participants will be advised to take the study medication once daily, preferably at bedtime. The intervention will not replace or interfere with routine antenatal care, and all co-interventions will be documented.
Participants will be followed throughout pregnancy during scheduled antenatal visits. Follow-up assessments will include monitoring of blood pressure, urine protein testing, evaluation for clinical features of hypertensive disorders of pregnancy, and assessment of adherence to the study medication. Compliance will be evaluated using participant self-reporting and pill counts.
Safety monitoring is an integral component of the study. Adverse events and serious adverse events will be actively monitored throughout the study period. A predefined safety monitoring and Serious Adverse Event (SAE) management plan is in place, consistent with ICH Good Clinical Practice (GCP) guidelines and the Ethical Guidelines for Health Research in Nepal. Any SAE will be promptly managed according to standard institutional clinical protocols, with immediate discontinuation of the investigational product if indicated. Causality assessment will be performed using the WHO-UMC criteria, and SAEs will be reported to the Institutional Review Committee and the Nepal Health Research Council Ethical Review Board within required timelines.
An independent Data Safety Monitoring Board (DSMB) will periodically review accumulated safety data and provide recommendations regarding study continuation, modification, or termination based on safety considerations.
Study data will be collected using structured case report forms and entered into a secure electronic database. Participant confidentiality will be maintained by assigning unique study identification numbers. Identifiable information will be stored separately from clinical data and accessed only by authorized study personnel. Data quality assurance measures include regular data checks, monitoring, and adherence to standard operating procedures.
The study aims to generate locally relevant evidence regarding the optimal prophylactic dose of Aspirin for the prevention of preeclampsia in high-risk pregnant women in Nepal. Given the low cost, wide availability, and established safety profile of low-dose Aspirin, the findings may inform clinical practice and contribute to improved maternal health outcomes in resource-limited settings.
918 studies on the registry are indexed under Pre-Eclampsia; 243 are open to participants now.
This study's planned enrollment of 86 is below the median of 110 across 482 interventional studies indexed under Pre-Eclampsia.
Browse Pre-Eclampsia studies →This is the only study on the registry with Dr. Sunita Pun as lead sponsor.
Compared within Pre-Eclampsia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hypertension, Pregnancy-Induced. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Known to aspirin, uncontrolled asthma with NSAID sensitivity
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Interventional
Drug: Aspirin
Interventional
Drug: Aspirin
This interventional study is being doe in pregnant women after calculationg their Gestosis score and if Gestosis score of 3 or more, they will be randomised into aspirin 75mg and aspirin 150mg in the ratio 1:1. After their delivery, the result will be recorded as to whether preeclampsia had been prevented.
Incidence of Preeclampsia
Preeclampsia will be assessed during routine antenatal visits and at delivery by trained obstetric clinicians. Blood pressure will be measured using a calibrated sphygmomanometer with the participant in a seated position after adequate rest. Hypertension will be defined as systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg recorded on two occasions at least 4 hours apart after 20 weeks of gestation. Proteinuria will be assessed using urine dipstick testing (≥1+) or 24-hour urine protein estimation (≥300 mg). In the absence of proteinuria, preeclampsia will be diagnosed based on hypertension with evidence of maternal end-organ dysfunction. The incidence of preeclampsia will be recorded after the the time of randomization until delivery .
Time frame: 1 year (After the time of randomization till delivery)
No study locations are listed for this record.
Start is estimated for Jan 2026; primary completion for Dec 2026, 11 months later.
Of 35 phase 4 interventional studies under Pre-Eclampsia, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 35. This study's planned 11 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aspirin